Targeting Tumor-Immune Cells with a Fusion Protein
Author Information
Author(s): Sun Jialin, Zhao Lina, Teng Lijie, Lin Feng, Zhang Hongna, Li Zhengnan, Gao Qiang
Primary Institution: Key Laboratory of Industrial Microbiology, Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, People's Republic of China
Hypothesis
Can a fusion protein of epidermal growth factor and staphylococcal enterotoxin effectively target and enhance the immune response against solid tumors?
Conclusion
The EGF-SEA fusion protein significantly inhibited the growth of solid tumors by enhancing the infiltration and activation of cytotoxic T lymphocytes.
Supporting Evidence
- The EGF-SEA fusion protein significantly reduced tumor weight compared to control.
- Increased levels of cytokines TNF-α and IFN-γ were observed in tumors treated with EGF-SEA.
- The study demonstrated effective targeting of T lymphocytes to tumor sites using EGF-SEA.
Takeaway
Researchers created a special protein that helps immune cells find and attack tumors better, which could help treat cancer.
Methodology
Mice were injected with tumor cells and treated with either saline, SEA, or EGF-SEA, followed by tumor measurement and analysis of immune responses.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Male ICR mice, 4-5 weeks old.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 0.54 to 1.37
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website